Can a Ketogenic Diet Support Cancer Treatment? Evidence, Benefits, and Risks

A ketogenic (very‑low‑carbohydrate) diet is being investigated for its potential role in cancer therapy and prevention. While some pre‑clinical and early‑clinical data are encouraging, the evidence remains mixed and the diet may pose challenges for patients undergoing active treatment.

Cancer is typically managed with a combination of surgery, chemotherapy, and radiation. Numerous dietary strategies have been studied, but none has yet demonstrated consistent, clinically meaningful benefit.

Early laboratory work suggests that markedly restricting carbohydrates could slow tumor growth, but human data are limited.

Important note

Do not postpone or replace standard cancer therapy with a ketogenic diet or any other alternative approach. Discuss all nutrition plans with your oncology team.

Carbohydrates raise blood‑glucose levels, providing a readily usable fuel for both normal and malignant cells. By dramatically lowering carbohydrate intake, a ketogenic diet reduces circulating glucose and insulin, which some researchers propose may “starve” cancer cells, leading to slower proliferation and smaller tumor size.

It is a misconception that eliminating sugar will completely halt cancer growth—tumor cells can also metabolize fats and amino acids. Nonetheless, reduced glucose availability may modestly impede tumor progression.

Key metabolic effects of a ketogenic diet that could influence cancer biology include:

• Lower insulin levels: Insulin can promote cell division, including that of cancer cells. Reduced insulin may dampen tumor growth.
• Elevated ketone bodies: Many cancer cells are inefficient at using ketones for energy. Animal studies have shown that ketones can suppress tumor expansion.

Animal evidence

A 2019 mouse study demonstrated that a diet providing only 0.1 % of calories from carbohydrates limited the growth of squamous‑cell carcinoma in the lung and esophagus. When combined with the diabetes medication canagliflozin, tumor inhibition was even greater. The diet alone did not shrink established tumors, but pairing it with the chemotherapy agent cisplatin produced measurable tumor reduction. Similar synergistic effects were observed with phosphoinositide 3‑kinase (PI3K) inhibitors, likely because of the diet‑induced drop in insulin.

Human research

Human data are still emerging and largely consist of case reports or small trials.

Brain‑cancer investigations

Glioblastoma, an aggressive brain tumor, has been a focal point of research. A 2010 case report described a 65‑year‑old woman who, after tumor resection, followed a very‑low‑calorie ketogenic diet. Tumor progression slowed during the diet but accelerated once she returned to a regular eating pattern. Earlier case reports from 1995 involving two adolescent girls with advanced brain cancer showed decreased glucose uptake in their tumors while on the diet; one girl reported improved quality of life and remained progression‑free for 12 months.

A 2018 pilot study found the diet to be safe and suggested it might augment standard therapies, but the sample size was too small for definitive conclusions.

Other cancer types

In a 2018 randomized controlled trial, women with ovarian or endometrial cancer who followed a ketogenic diet for 12 weeks reported better physical function—such as climbing stairs—compared with peers on a high‑fiber, low‑fat American Cancer Society diet. Additional reported benefits included higher energy levels and fewer cravings for refined carbohydrates.

A 2020 study of 81 patients with rectal or breast cancer receiving radiation or chemotherapy observed reduced fat mass and preservation of skeletal muscle in participants who adhered to a ketogenic regimen.

Quality‑of‑life outcomes

Another 2020 randomized trial involving 80 individuals with advanced or metastatic breast cancer found no overall difference in quality of life after 12 weeks, yet the ketogenic group reported a modest improvement in global quality‑of‑life scores at the 6‑week mark.

Potential influence on growth‑factor pathways

A 2024 investigation of a 21‑day ketogenic protocol reported lowered circulating insulin‑like growth factor‑1 (IGF‑1), a hormone that can stimulate cell proliferation. Reduced IGF‑1 may theoretically diminish long‑term cancer risk.

Implications for diabetes and obesity

People with diabetes have higher incidence of several cancers, including hepatocellular, pancreatic, endometrial, colorectal, breast, and bladder cancers. Because ketogenic eating can improve glycemic control, it might indirectly lower cancer risk in this population.

Obesity is a well‑documented risk factor for at least 18 cancer types. A 2023 cohort study of 2.6 million Catalan adults linked early‑adult obesity with elevated cancer risk. Given the diet’s efficacy for weight loss, it could contribute to risk reduction by addressing obesity.

Professional consensus and safety considerations

Despite promising pre‑clinical findings, leading oncology societies do not currently endorse the ketogenic diet as a primary preventive or therapeutic strategy for cancer. The diet carries potential drawbacks:

• High saturated‑fat content: Many allowed foods—e.g., red meat—are associated with increased risk of certain cancers.
• Restrictive nature: Excluding whole grains, many fruits, and a variety of vegetables may limit intake of cancer‑protective phytonutrients and fiber.
• Risk of unintended weight loss: Cancer patients often struggle to meet caloric needs; a low‑carb regimen can exacerbate malnutrition.
• Adherence challenges: The strict macronutrient targets can be difficult to sustain, especially when food is a source of comfort during treatment.

For these reasons, the diet should only be considered under medical supervision, ideally as an adjunct to conventional therapy.

If you are interested in trying a ketogenic approach, consult your oncologist and a registered dietitian experienced in oncology nutrition. They can assess suitability, monitor nutritional status, and ensure the plan does not interfere with prescribed treatments.

In summary, a ketogenic diet may offer modest metabolic benefits that could complement standard cancer care, but current evidence is insufficient to recommend it as a stand‑alone therapy. Ongoing, well‑designed clinical trials are needed to clarify its role.